Heart Failure
We recommend
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…
Articles on this topic
Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?
A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the…
Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for…
Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of…
Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing…
EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
Prague, March 8, 2022 – Hundreds of thousands of patients in the Czech Republic can soon look…
Does gliflozin treatment for heart failure have greater benefits in diabetics?
Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic…
Proposal of a New Treatment Sequence Algorithm for Heart Failure with Reduced Ejection Fraction
John McMurray and Milton Packer published a proposal for a new treatment sequence algorithm…
Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether…
Empagliflozin in the Treatment of Patients with Chronic Heart Failure
Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk…
Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Summary of New American Recommendations for Heart Failure Management
- EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
- Cardio-renal-metabolic syndrome in context
- The Latest Updates of ESC Recommendations for Heart Failure Treatment
Journal on this topic
Related topic